C. A. Naranjo

12.9k total citations · 1 hit paper
42 papers, 9.4k citations indexed

About

C. A. Naranjo is a scholar working on Cellular and Molecular Neuroscience, Pharmacology and Psychiatry and Mental health. According to data from OpenAlex, C. A. Naranjo has authored 42 papers receiving a total of 9.4k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cellular and Molecular Neuroscience, 9 papers in Pharmacology and 8 papers in Psychiatry and Mental health. Recurrent topics in C. A. Naranjo's work include Neurotransmitter Receptor Influence on Behavior (14 papers), Substance Abuse Treatment and Outcomes (6 papers) and Alcoholism and Thiamine Deficiency (6 papers). C. A. Naranjo is often cited by papers focused on Neurotransmitter Receptor Influence on Behavior (14 papers), Substance Abuse Treatment and Outcomes (6 papers) and Alcoholism and Thiamine Deficiency (6 papers). C. A. Naranjo collaborates with scholars based in Canada, United States and Chile. C. A. Naranjo's co-authors include Edward M. Sellers, U. Busto, E A Roberts, C Domecq, D J Greenblatt, Inés Ruiz, E Janecek, Paul Sandor, Karen E. Bremner and Della Knoke and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, Psychopharmacology and Clinical Pharmacology & Therapeutics.

In The Last Decade

C. A. Naranjo

42 papers receiving 8.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A method for estimating the probability of adverse drug reactions

1981 8.4k citations C. A. Naranjo, U. Busto et al. Clinical Pharmacology & Therapeutics profile →

Peers

Countries citing papers authored by C. A. Naranjo

Since Specialization

Citations

This map shows the geographic impact of C. A. Naranjo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. A. Naranjo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. A. Naranjo more than expected).

Fields of papers citing papers by C. A. Naranjo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. A. Naranjo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. A. Naranjo. The network helps show where C. A. Naranjo may publish in the future.

Co-authorship network of co-authors of C. A. Naranjo

This figure shows the co-authorship network connecting the top 25 collaborators of C. A. Naranjo. A scholar is included among the top collaborators of C. A. Naranjo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. A. Naranjo. C. A. Naranjo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems 2003 ·Addiction ·C. A. Naranjo, Karen E. Bremner, Krista L. Lanctôt	23
2	Ritanserin, a central 5-HT2 antagonist, in heavy social drinkers: desire to drink, alcohol intake and related effects 2003 ·Addiction ·C. A. Naranjo, Constantine X. Poulos, Krista L. Lanctôt, Karen E. Bremner, (unknown), (unknown)	6
3	A k-nearest neighborhood based fuzzy reasoning schema 2002 ·(unknown), Beth Sproule, C. A. Naranjo	2
4	Ritanserin In Relapse Prevention In Abstinent Alcoholics: Results From a Placebo‐Controlled Double‐Blind International Multicenter Trial 1999 ·Alcoholism Clinical and Experimental Research ·Gerhard A. Wiesbeck, H.‐G. Weijers, Jonathan Chick, C. A. Naranjo, Jobst Boening, (unknown)	30
5	Long‐acting injectable bromocriptine does not reduce relapse in alcoholics 1997 ·Addiction ·C. A. Naranjo, M Dongier, Karen E. Bremner	38
6	Paroxetine potentiates CNS side-effects of perphenazine. 1996 ·Clinical Pharmacology & Therapeutics ·Vural Özdemir, Nathan Herrmann, Scott E. Walker, W. Kalow, C. A. Naranjo	2
7	Bayesian evaluation of spontaneous reports of pancreatitis. 1996 ·Clinical Pharmacology & Therapeutics ·Krista L. Lanctôt, (unknown), U. Busto, C. A. Naranjo	1
8	Low endogenous dopamine function in brain predisposes to high alcohol preference and consumption: reversal by increasing synaptic dopamine. 1995 ·Journal of Pharmacology and Experimental Therapeutics ·Susan R. George, (unknown), Gordon Ng, Suna Jung, Brian F. O’Dowd, C. A. Naranjo	91
9	Ritanserin, a central 5-HT2 antagonist, in heavy social drinkers: desire to drink, alcohol intake and related effects 1995 ·Addiction ·C. A. Naranjo, Constantine X. Poulos, Krista L. Lanctôt, Karen E. Bremner, (unknown), (unknown)	11
10	Serotonin-altering medications and desire, consumption and effects of alcohol-treatment implications 1994 ·Birkhäuser Basel eBooks ·C. A. Naranjo, Karen E. Bremner	28
11	Fluoxetine attenuates alcohol intake and desire to drink 1994 ·International Clinical Psychopharmacology ·C. A. Naranjo, Constantine X. Poulos, Karen E. Bremner, Krista L. Lanctôt	66
12	Behavioural correlates of alcohol intoxication 1993 ·Addiction ·C. A. Naranjo, Karen E. Bremner	51
13	NOVEL NEUROPHARMACOLOGICAL TREATMENTS OF ALCOHOL DEPENDENCE 1992 ·Clinical Neuropharmacology ·C. A. Naranjo, (unknown), Karen E. Bremner	5
14	Kinetic and dynamic interactions of oral viqualine and ethanol in man 1989 ·European Journal of Clinical Pharmacology ·John T. Sullivan, C. A. Naranjo, (unknown), Howard L. Kaplan, K Kadlec, Edward M. Sellers	9
15	Withdrawal reaction after long-term therapeutic use of benzodiazepines 1987 ·Journal of Clinical Psychopharmacology ·U. Busto, Edward M. Sellers, C. A. Naranjo, Howard Cappell, Martha Sanchez‐Craig, K.V. Sýkora	7
16	The Role of Drugs in the Treatment of Alcoholism 1984 ·Drugs ·John E. Peachey, C. A. Naranjo	27
17	Nonfatty acid–modulated variations in drug binding due to heparin 1982 ·Clinical Pharmacology & Therapeutics ·C. A. Naranjo, V Khouw, Edward M. Sellers	8
18	A method for estimating the probability of adverse drug reactions breakdown → 1981 ·Clinical Pharmacology & Therapeutics ·C. A. Naranjo, U. Busto, Edward M. Sellers, Paul Sandor, Inés Ruiz, E A Roberts, E Janecek, C Domecq, D J Greenblatt	8382
19	Disposition of intravenous diazepam in young men and women 1981 ·European Journal of Clinical Pharmacology ·(unknown), Edward M. Sellers, C. A. Naranjo, Richard C. Frecker, David J. Greenblatt	16
20	Variability in heparin effect on serum drug binding 1980 ·Clinical Pharmacology & Therapeutics ·C. A. Naranjo, Edward M. Sellers, V Khouw, Peter B. Alexander, (unknown), Julie Shaw	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact